Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Barzolvolimab · CDX-0159

Monoclonal antibody · Acts on KIT · developed by Celldex Therapeutics

Phase 3 Most advanced trial

CLDX Developer

2 Registered trials

What is Barzolvolimab?

Barzolvolimab (CDX-0159) is an antibody administered intravenously or subcutaneously.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CDX-0159
Drug type: Monoclonal antibody
Targets: KIT
Mechanism: Acts on KIT
Therapy area: Dermatology, Immunology
Developer: Celldex Therapeutics (CLDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 4B77GX0NA3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06445023	Phase 3	Chronic Spontaneous Urticaria	Active not recruiting	CLDX
NCT04944862	Phase 1	Prurigo Nodularis	Completed	CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Spontaneous UrticariaPrurigo Nodularis

Other drugs acting on KIT

Midostaurin FDA approved Pexidartinib FDA approved Regorafenib FDA approved Sunitinib FDA approved Bezuclastinib Phase 3 Briquilimab Phase 1/2 CDX 0158 Phase 1 Olverembatinib Phase 3 Sitravatinib Phase 3

More from Celldex Therapeutics

CDX 0158 Phase 1 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-1307 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-585 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Keyhole Limpet Hemocyanin Phase 2 Rindopepimut Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind Barzolvolimab

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z